|  |  |  |  |  |  | CYP17 (A2/A2 versus A1/A1) and breast cancer |  | |||
---|---|---|---|---|---|---|---|---|---|---|---|
 |  |  |  |  |  |  | All cases | Advanced cases |  | ||
Ref | Study design | Race/ethnicity | Age of patients (years) | Age of control individuals (years) | Cases (n) | Advanced cases (n) | OR | 95% CI | OR | 95% CI | HRT use considered? |
[7*] | Nested case-control | Afro-American, Asian, Latina | 63.0 ± 8.4 | 61.4 ± 8.3 | 174* | 40 | 1.32†| 0.87-2.0 | 2.5†| 1.07-5.94 | No |
[16] | Case-control | White | <55 | 45-74 | 835 | 24 | 1.17 | 0.92-1.49 | 0.88†| 0.38-2.01 | No |
[17] | Nested case-control | White | 60.4 ± 11.7 | 60.2 ± 11.5 | 115 | 30 | 0.89 | 0.41-1.95 | 1.39 | 0.26-7.28 | Yes |
[18] | Case-control | Afro-American | Not given | Not given | 76 | 21 | 1.40†| 0.44-4.38 | 0.6†| 0.1-4.0 | No |
 |  | Latina |  |  | 20 | 7 | 1.93†| 0.75-5.01 | 0.2†| 0.0-1.3 |  |
 |  | White |  |  | 27 | 10 | 0.80†| 0.45-1.43 | 1.7†| 0.6-5.1 |  |
[19*] | Nested case-control | White | 58.3 ± 7.1‡ |  | 464 | 107 | 0.91 | 0.61-1.34 | 0.84†| 0.54-1.32 | Yes |
[9*] | Case-control | Taiwanese | Not given | Not given | 150 | Not given | 1.28 | 0.73-2.27 | Â | Â | Yes |
[20] | Case-control | White | 59 (27-91) | 20-44 | 510 | 93§ | 0.94 | 0.54-1.65 | 1.38§ | 0.62-3.06 | No |